{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:55:55Z","timestamp":1781650555685,"version":"3.54.5"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Nationaal MS Fonds","award":["OZ2023-012"],"award-info":[{"award-number":["OZ2023-012"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol. Res. Pract."],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Multiple sclerosis (MS) is the most common demyelinating disease of the central nervous system. Over the past years, spinal cord MRI (SC-MRI) has improved significantly in quality and has become an important part of the diagnostic workup for MS. Presently, follow-up imaging of the spinal cord is mainly performed when spinal cord related symptoms occur. However, there is increasing evidence that asymptomatic cord lesions can occur independently of brain disease activity. Even asymptomatic spinal cord lesions have been shown to be a poor prognostic factor regarding future disability accrual. Additionally, the association between (asymptomatic) spinal cord lesions and progression independent of relapse activity (PIRA) remains undefined. Prospective data on the frequency and importance of asymptomatic spinal cord lesions, and therefore the potential role of SC-MRI in treatment monitoring, is lacking.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n We will routinely scan the whole spinal cord (as well as routine brain MRI) to prospectively collect SC-MRI data, in addition to clinical parameters, blood-biomarkers and CSF, in recently diagnosed MS patients. The goal is to assess the incidence of asymptomatic spinal cord lesions in patients commencing disease modifying treatment (DMT) for the first time. It will be assessed how often disease activity is solely proven by SC-MRI. A secondary objective is to identify patient groups predisposed to developing new spinal cord lesions during follow-up in early disease.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This will be a multicentre, prospective longitudinal, observational study. The study population consists of relapsing-remitting MS patients, between 18 and 65 years old, initiating their first DMT within 5 years of the first clinical event. We aim to include 155 patients, who will receive three yearly SC-MRI (both sagittal and axial), brain MRI and biomarker assays during follow-up of 27 months.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n This study started in August 2024. Currently, inclusion is still ongoing.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n The goal of this study is to explore the incidence of asymptomatic spinal cord lesions in early MS and to identify prognostic factors for spinal cord disease activity.<\/jats:p>\n <\/jats:sec>\n \n Trial registration<\/jats:title>\n \n This study has been registered in the Dutch CCMO\/OMON Registry under\n NL-005846<\/jats:bold>\n at 12\/03\/2024 (\n https:\/\/onderzoekmetmensen.nl\/nl\/trial\/56629<\/jats:ext-link>\n ) and in ClinicalTrials.gov under registration number\n NCT06827834.<\/jats:bold>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1186\/s42466-026-00465-9","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T12:13:29Z","timestamp":1776428009000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["MSpine: a prospective longitudinal study of spinal cord lesions in multiple sclerosis: MRI monitoring and prognostic factors for active disease. A study protocol"],"prefix":"10.1186","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6141-5261","authenticated-orcid":false,"given":"Demmie","family":"Bouweriks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Kreiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie A. M.","family":"Knippenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan G. M. C.","family":"Damoiseaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Smolders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen J. J.","family":"van Eijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elwin H. H.","family":"Mommers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet W. K.","family":"de Beukelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom B. G.","family":"Olde Dubbelink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey H. H.","family":"Merry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond M. M.","family":"Hupperts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver H. H.","family":"Gerlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"issue":"3","key":"465_CR1","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1001\/jamaneurol.2013.5993","volume":"71","author":"A Ascherio","year":"2014","unstructured":"Ascherio, A., Munger, K. L., White, R., K\u00f6chert, K., Simon, K. C., Polman, C. H., Freedman, M. S., Hartung, H., Miller, D. H., Montalb\u00e1n, X., Edan, G., Barkhof, F., Pleimes, D., Rad\u00fc, E., Sandbrink, R., Kappos, L., & Pohl, C. (2014). Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurology, 71(3), 306\u2013314. https:\/\/doi.org\/10.1001\/jamaneurol.2013.5993","journal-title":"JAMA Neurology"},{"issue":"8","key":"465_CR2","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1093\/brain\/awz156","volume":"142","author":"WJ Brownlee","year":"2019","unstructured":"Brownlee, W. J., Altmann, D. R., Prados, F., Miszkiel, K. A., Eshaghi, A., Gandini Wheeler-Kingshott, C. A. M., Barkhof, F., & Ciccarelli, O. (2019). Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis. Brain, 142(8), 2276\u20132287. https:\/\/doi.org\/10.1093\/brain\/awz156","journal-title":"Brain"},{"issue":"6","key":"465_CR3","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1111\/jon.12553","volume":"28","author":"C Casserly","year":"2018","unstructured":"Casserly, C., Seyman, E. E., Alcaide-Leon, P., Guenette, M., Lyons, C., Sankar, S., Svendrovski, A., Baral, S., & Oh, J. (2018). Spinal cord atrophy in multiple sclerosis: A systematic review and meta-analysis. Journal of Neuroimaging\u202f: Official Journal of the American Society of Neuroimaging, 28(6), 556\u2013586. https:\/\/doi.org\/10.1111\/jon.12553","journal-title":"Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging"},{"issue":"1","key":"465_CR4","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209444","volume":"103","author":"O Ciccarelli","year":"2024","unstructured":"Ciccarelli, O., Barkhof, F., Calabrese, M., De Stefano, N., Eshaghi, A., Filippi, M., Gasperini, C., Granziera, C., Kappos, L., Rocca, M. A., Rovira, \u00c0., Sastre-Garriga, J., Sormani, M. P., Tur, C., & Toosy, A. T. (2024). Using the progression independent of relapse activity framework to unveil the pathobiological foundations of multiple sclerosis. Neurology, 103(1), Article e209444. https:\/\/doi.org\/10.1212\/WNL.0000000000209444","journal-title":"Neurology"},{"key":"465_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101009","volume":"44","author":"M Di Filippo","year":"2024","unstructured":"Di Filippo, M., Gaetani, L., Centonze, D., Hegen, H., Kuhle, J., Teunissen, C. E., Tintor\u00e9, M., Villar, L. M., Willemse, E. A. J., Zetterberg, H., & Parnetti, L. (2024). Fluid biomarkers in multiple sclerosis: From current to future applications. The Lancet Regional Health - Europe, 44, Article 10.1016\/j.lanepe.2024.101009.","journal-title":"The Lancet Regional Health - Europe"},{"issue":"6","key":"465_CR6","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1007\/s00415-021-10901-2","volume":"269","author":"E Di Sabatino","year":"2022","unstructured":"Di Sabatino, E., Gaetani, L., Sperandei, S., Fiacca, A., Guercini, G., Parnetti, L., & Di Filippo, M. (2022). The no evidence of disease activity (NEDA) concept in MS: Impact of spinal cord MRI. Journal of Neurology, 269(6), 3129\u20133135. https:\/\/doi.org\/10.1007\/s00415-021-10901-2","journal-title":"Journal of Neurology"},{"issue":"6","key":"465_CR7","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nri2550","volume":"9","author":"J Goverman","year":"2009","unstructured":"Goverman, J. (2009). Autoimmune T cell responses in the central nervous system. Nature Reviews Immunology, 9(6), 393\u2013407. https:\/\/doi.org\/10.1038\/nri2550","journal-title":"Nature Reviews Immunology"},{"issue":"12","key":"465_CR8","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1007\/s00415-019-09526-3","volume":"266","author":"F Granella","year":"2019","unstructured":"Granella, F., Tsantes, E., Graziuso, S., Bazzurri, V., Crisi, G., & Curti, E. (2019). Spinal cord lesions are frequently asymptomatic in relapsing-remitting multiple sclerosis: A retrospective MRI survey. Journal of Neurology, 266(12), 3031\u20133037. https:\/\/doi.org\/10.1007\/s00415-019-09526-3","journal-title":"Journal of Neurology"},{"issue":"1\u20132","key":"465_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jneuroim.2011.02.009","volume":"234","author":"S Hagman","year":"2011","unstructured":"Hagman, S., Raunio, M., Rossi, M., Dastidar, P., & Elovaara, I. (2011). Disease-associated inflammatory biomarker profiles in blood in different subtypes of multiple sclerosis: Prospective clinical and MRI follow-up study. Journal of Neuroimmunology, 234(1\u20132), 141\u2013147. https:\/\/doi.org\/10.1016\/j.jneuroim.2011.02.009","journal-title":"Journal of Neuroimmunology"},{"issue":"24","key":"465_CR10","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1212\/WNL.0000000000004716","volume":"89","author":"K Kowalec","year":"2017","unstructured":"Kowalec, K., McKay, K. A., Patten, S. B., Fisk, J. D., Evans, C., Tremlett, H., Marrie, R. A., CIHR Team in Epidemiology and Impact of Comorbidity on Multiple Sclerosis (ECoMS). (2017). Comorbidity increases the risk of relapse in multiple sclerosis: A prospective study. Neurology, 89(24), 2455\u20132461. https:\/\/doi.org\/10.1212\/WNL.0000000000004716","journal-title":"Neurology"},{"key":"465_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104994","volume":"79","author":"D Kreiter","year":"2023","unstructured":"Kreiter, D., Spee, R., Merry, A., Hupperts, R., & Gerlach, O. (2023). Effect of disease-modifying treatment on spinal cord lesion formation in multiple sclerosis: A retrospective observational study. Multiple Sclerosis and Related Disorders, 79, Article 104994. https:\/\/doi.org\/10.1016\/j.msard.2023.104994","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"465_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-024-01115-x","author":"D Kreiter","year":"2024","unstructured":"Kreiter, D., Kalincik, T., Hupperts, R., Patti, F., Spitaleri, D., Foschi, M., Surcinelli, A., Maimone, D., Yamout, B., & Khoury, S. J. (2024a). Effectiveness of disease-modifying treatment on spinal cord lesion formation in relapse-onset multiple sclerosis: An MSBase registry study. CNS Drugs. 38(11), 921\u2013930 https:\/\/doi.org\/10.1007\/s40263-024-01115-x","journal-title":"CNS Drugs"},{"key":"465_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2023.122846","volume":"456","author":"D Kreiter","year":"2024","unstructured":"Kreiter, D., Postma, A. A., Hupperts, R., & Gerlach, O. (2024b). Hallmarks of spinal cord pathology in multiple sclerosis. Journal of the Neurological Sciences, 456, Article 122846. https:\/\/doi.org\/10.1016\/j.jns.2023.122846","journal-title":"Journal of the Neurological Sciences"},{"key":"465_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102391","volume":"45","author":"MR Mahler","year":"2020","unstructured":"Mahler, M. R., S\u00f8ndergaard, H. B., Buhelt, S., von Essen, M. R., Romme Christensen, J., Enevold, C., & Sellebjerg, F. (2020). Multiplex assessment of cerebrospinal fluid biomarkers in multiple sclerosis. Multiple Sclerosis and Related Disorders, 45, Article 102391. https:\/\/doi.org\/10.1016\/j.msard.2020.102391","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"3","key":"465_CR15","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.4049\/jimmunol.182.3.1541","volume":"182","author":"LM Maier","year":"2009","unstructured":"Maier, L. M., Anderson, D. E., Severson, C. A., Baecher-Allan, C., Healy, B., Liu, D. V., Wittrup, K. D., De Jager, P. L., & Hafler, D. A. (2009). Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses. Journal of Immunology, 182(3), 1541\u20131547. https:\/\/doi.org\/10.4049\/jimmunol.182.3.1541","journal-title":"Journal of Immunology"},{"issue":"1","key":"465_CR16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1056\/NEJMoa020696","volume":"348","author":"DH Miller","year":"2003","unstructured":"Miller, D. H., Khan, O. A., Sheremata, W. A., Blumhardt, L. D., Rice, G. P. A., Libonati, M. A., Willmer-Hulme, A. J., Dalton, C. M., Miszkiel, K. A., O\u2019Connor, P. W., International Natalizumab Multiple Sclerosis Trial Group. (2003). A controlled trial of natalizumab for relapsing multiple sclerosis. New England Journal of Medicine, 348(1), 15\u201323. https:\/\/doi.org\/10.1056\/NEJMoa020696","journal-title":"New England Journal of Medicine"},{"key":"465_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577664","volume":"358","author":"M Mimpen","year":"2021","unstructured":"Mimpen, M., Damoiseaux, J., van Doorn, W., Rolf, L., Muris, A., Hupperts, R., van Luijn, M. M., Gerlach, O., & Smolders, J. (2021). Proportions of circulating transitional B cells associate with MRI activity in interferon beta-treated multiple sclerosis patients. Journal of Neuroimmunology, 358, Article 577664. https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577664","journal-title":"Journal of Neuroimmunology"},{"issue":"1","key":"465_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s42466-025-00387-y","volume":"7","author":"M Pawlitzki","year":"2025","unstructured":"Pawlitzki, M., Stahmann, A., Frahm, N., Kirstein, M., Peters, M., Flachenecker, P., & Ellenberger, D. (2025). From routine to selective: How updated MRI guidelines reshape gadolinium use in Germany. Neurological Research and Practice, 7(1), 33. https:\/\/doi.org\/10.1186\/s42466-025-00387-y","journal-title":"Neurological Research and Practice"},{"issue":"1","key":"465_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s42466-024-00339-y","volume":"6","author":"C Reinhardt","year":"2024","unstructured":"Reinhardt, C., Angstwurm, K., Freudenstein, D., Lee, D., Wendl, C., & Linker, R. A. (2024). Reinhardt<\/Emphasis> Neurological Research and Practice, 6(1), Article 40. https:\/\/doi.org\/10.1186\/s42466-024-00339-y","journal-title":"Neurological Research and Practice"},{"issue":"2","key":"465_CR20","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1001\/jamaneurol.2014.3537","volume":"72","author":"DL Rotstein","year":"2015","unstructured":"Rotstein, D. L., Healy, B. C., Malik, M. T., Chitnis, T., & Weiner, H. L. (2015). Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurology, 72(2), 152\u2013158. https:\/\/doi.org\/10.1001\/jamaneurol.2014.3537","journal-title":"JAMA Neurology"},{"issue":"3","key":"465_CR21","doi-asserted-by":"publisher","first-page":"158","DOI":"10.7224\/1537-2073.2016-068","volume":"19","author":"S Tummala","year":"2017","unstructured":"Tummala, S., Singhal, T., Oommen, V. V., Kim, G., Khalid, F., Healy, B. C., & Bakshi, R. (2017). Spinal cord as an adjunct to brain magnetic resonance imaging in defining \u201cNo Evidence of Disease Activity\u201d in multiple sclerosis. International Journal of MS Care, 19(3), 158\u2013164. https:\/\/doi.org\/10.7224\/1537-2073.2016-068","journal-title":"International Journal of MS Care"},{"issue":"6","key":"465_CR22","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1177\/1352458515599246","volume":"22","author":"C Zecca","year":"2016","unstructured":"Zecca, C., Disanto, G., Sormani, M. P., Riccitelli, G. C., Cianfoni, A., Del Grande, F., Pravat\u00e0, E., & Gobbi, C. (2016). Relevance of asymptomatic spinal MRI lesions in patients with multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England), 22(6), 782\u2013791. https:\/\/doi.org\/10.1177\/1352458515599246","journal-title":"Multiple Sclerosis (Houndmills, Basingstoke, England)"}],"container-title":["Neurological Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-026-00465-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42466-026-00465-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-026-00465-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:17:39Z","timestamp":1781648259000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s42466-026-00465-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["465"],"URL":"https:\/\/doi.org\/10.1186\/s42466-026-00465-9","relation":{},"ISSN":["2524-3489"],"issn-type":[{"value":"2524-3489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This protocol was considered and approved by the ethics committee \u2018Medisch Ethische Toetsingscommissie Zuyderland (METC-Z)\u2019 (Reference number 2024-0014, 12.03.2024). This work will comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2013 and in accordance with the Medical Research Involving Human Subjects Act (WMO). Only patients with a signed informed consent form are included. The first patient was included in August, 2024 and currently inclusion is still ongoing.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable, no data related to individual persons will be published.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}